Drug intelligence / Profile preview

CP-001 (Alessa Therapeutics)

Development stage: Unknown
Lead developer: Alessa Therapeutics
Modality: Small Molecules
Administration: Implant

Overview

**CP-001** is Alessa Therapeutics' Biolen drug-eluting intraprostatic implant for benign prostatic hyperplasia. The product provides sustained, localized delivery of **bicalutamide**, a nonsteroidal androgen-receptor antagonist, directly within the prostate to suppress androgen-receptor signaling while seeking to minimize systemic exposure. Alessa's pipeline identifies CP-001 as the bicalutamide-implant component of the Biolen program and states that, following a completed Phase 1 study in early-stage prostate cancer, Biolen is intended to proceed in BPH. ([alessatherapeutics.com](https://alessatherapeutics.com/science/pipeline/))

Brand names: Biolen
Other names: bicalutamide implant

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on CP-001 (Alessa Therapeutics).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CP-001 (Alessa Therapeutics).

Explore the full profile